At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 550 enrolled
Drug / intervention
Etanercept +2 moredrug
Likely dose
Etanercept 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating Etanercept and Methotrexate for Arthritis, Rheumatoid. Completed, enrolled 550 participants across 41 sites.
Detailed Summary
The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedMar 2007
Primary CompletionJul 2010
TodayJul 2026
First PostedMar 9, 2007
Enrollment StartJul 1, 2006
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 19.3 years ago
Interventions
Etanerceptdrug
10 mg twice weekly, subcutaneous injection for 52 weeks
Etanerceptdrug
25 mg, twice weekly, subcutaneous injection for 52 weeks
Methotrexatedrug
up to 8 mg per week, oral dosing for 52 weeks